There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Background
Atopic eczema is a common and debilitating condition associated with depression and
anxiety, but the nature of this association remains unclear.
Objective
To explore the temporal relationship between atopic eczema and new depression/anxiety.
Methods
This matched cohort study used routinely collected data from the UK Clinical Practice
Research Datalink, linked to hospital admissions data. We identified adults with atopic
eczema (1998-2016) using a validated algorithm, and up to 5 individuals without atopic
eczema matched on date of diagnosis, age, sex, and general practice. We estimated
the hazard ratio (HR) for new depression/anxiety using stratified Cox regression to
account for age, sex, calendar period, Index of Multiple Deprivation, glucocorticoid
treatment, obesity, smoking, and harmful alcohol use.
Results
We identified 526,808 adults with atopic eczema who were matched to 2,569,030 without.
Atopic eczema was associated with increased incidence of new depression (HR, 1.14;
99% CI, 1.12-1.16) and anxiety (HR, 1.17; 99% CI, 1.14-1.19). We observed a stronger
effect of atopic eczema on depression with increasing atopic eczema severity (HR [99%
CI] compared with no atopic eczema: mild, 1.10 [1.08-1.13]; moderate, 1.19 [1.15-1.23];
and severe, 1.26 [1.17-1.37]). A dose-response association, however, was less apparent
for new anxiety diagnosis (HR [99% CI] compared with no atopic eczema: mild, 1.14
[1.11-1.18]; moderate, 1.21 [1.17-1.26]; and severe, 1.15; [1.05-1.25]).
Conclusions
Adults with atopic eczema are more likely to develop new depression and anxiety. For
depression, we observed a dose-response relationship with atopic eczema severity.
The Clinical Practice Research Datalink (CPRD) is an ongoing primary care database of anonymised medical records from general practitioners, with coverage of over 11.3 million patients from 674 practices in the UK. With 4.4 million active (alive, currently registered) patients meeting quality criteria, approximately 6.9% of the UK population are included and patients are broadly representative of the UK general population in terms of age, sex and ethnicity. General practitioners are the gatekeepers of primary care and specialist referrals in the UK. The CPRD primary care database is therefore a rich source of health data for research, including data on demographics, symptoms, tests, diagnoses, therapies, health-related behaviours and referrals to secondary care. For over half of patients, linkage with datasets from secondary care, disease-specific cohorts and mortality records enhance the range of data available for research. The CPRD is very widely used internationally for epidemiological research and has been used to produce over 1000 research studies, published in peer-reviewed journals across a broad range of health outcomes. However, researchers must be aware of the complexity of routinely collected electronic health records, including ways to manage variable completeness, misclassification and development of disease definitions for research.
Summary Background Measurement of changes in health across locations is useful to compare and contrast changing epidemiological patterns against health system performance and identify specific needs for resource allocation in research, policy development, and programme decision making. Using the Global Burden of Diseases, Injuries, and Risk Factors Study 2016, we drew from two widely used summary measures to monitor such changes in population health: disability-adjusted life-years (DALYs) and healthy life expectancy (HALE). We used these measures to track trends and benchmark progress compared with expected trends on the basis of the Socio-demographic Index (SDI). Methods We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 for all-cause mortality, cause-specific mortality, and non-fatal disease burden to derive HALE and DALYs by sex for 195 countries and territories from 1990 to 2016. We calculated DALYs by summing years of life lost and years of life lived with disability for each location, age group, sex, and year. We estimated HALE using age-specific death rates and years of life lived with disability per capita. We explored how DALYs and HALE differed from expected trends when compared with the SDI: the geometric mean of income per person, educational attainment in the population older than age 15 years, and total fertility rate. Findings The highest globally observed HALE at birth for both women and men was in Singapore, at 75·2 years (95% uncertainty interval 71·9–78·6) for females and 72·0 years (68·8–75·1) for males. The lowest for females was in the Central African Republic (45·6 years [42·0–49·5]) and for males was in Lesotho (41·5 years [39·0–44·0]). From 1990 to 2016, global HALE increased by an average of 6·24 years (5·97–6·48) for both sexes combined. Global HALE increased by 6·04 years (5·74–6·27) for males and 6·49 years (6·08–6·77) for females, whereas HALE at age 65 years increased by 1·78 years (1·61–1·93) for males and 1·96 years (1·69–2·13) for females. Total global DALYs remained largely unchanged from 1990 to 2016 (–2·3% [–5·9 to 0·9]), with decreases in communicable, maternal, neonatal, and nutritional (CMNN) disease DALYs offset by increased DALYs due to non-communicable diseases (NCDs). The exemplars, calculated as the five lowest ratios of observed to expected age-standardised DALY rates in 2016, were Nicaragua, Costa Rica, the Maldives, Peru, and Israel. The leading three causes of DALYs globally were ischaemic heart disease, cerebrovascular disease, and lower respiratory infections, comprising 16·1% of all DALYs. Total DALYs and age-standardised DALY rates due to most CMNN causes decreased from 1990 to 2016. Conversely, the total DALY burden rose for most NCDs; however, age-standardised DALY rates due to NCDs declined globally. Interpretation At a global level, DALYs and HALE continue to show improvements. At the same time, we observe that many populations are facing growing functional health loss. Rising SDI was associated with increases in cumulative years of life lived with disability and decreases in CMNN DALYs offset by increased NCD DALYs. Relative compression of morbidity highlights the importance of continued health interventions, which has changed in most locations in pace with the gross domestic product per person, education, and family planning. The analysis of DALYs and HALE and their relationship to SDI represents a robust framework with which to benchmark location-specific health performance. Country-specific drivers of disease burden, particularly for causes with higher-than-expected DALYs, should inform health policies, health system improvement initiatives, targeted prevention efforts, and development assistance for health, including financial and research investments for all countries, regardless of their level of sociodemographic development. The presence of countries that substantially outperform others suggests the need for increased scrutiny for proven examples of best practices, which can help to extend gains, whereas the presence of underperforming countries suggests the need for devotion of extra attention to health systems that need more robust support. Funding Bill & Melinda Gates Foundation.
Journal ID (iso-abbrev): J Allergy Clin Immunol Pract
Title:
The Journal of Allergy and Clinical Immunology. in Practice
Publisher:
Elsevier Inc
ISSN
(Print):
2213-2198
ISSN
(Electronic):
2213-2201
Publication date PMC-release: 1
January
2020
Publication date
(Print):
January
2020
Volume: 8
Issue: 1
Pages: 248-257.e16
Affiliations
[a
]Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and Population
Health, London School of Hygiene and Tropical Medicine, London, United Kingdom
[b
]Clalit Health Services, Department of Family Medicine, Rabin Medical Center, Petah
Tikva, Israel
[c
]Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv,
Israel
[d
]Division of Psychiatry, University College London, London, United Kingdom
[e
]Camden and Islington National Health Service (NHS) Foundation Trust, London, United
Kingdom
[f
]Department of Dermatology, University of California San Francisco, San Francisco,
Calif
[g
]Nottingham Support Group for Carers of Children with Eczema, Nottingham, United Kingdom
[h
]St John's Institute of Dermatology, Guy's & St Thomas' Hospital National Health Service
(NHS) Foundation Trust and King's College London, London, United Kingdom
[i
]Health Data Research UK, London, United Kingdom
Author notes
[∗
]Corresponding author: Kathryn E. Mansfield, MBBS, BSc, MRes, PhD, London School of
Hygiene and Tropical Medicine, London WC1E 7HT, UK.
kathryn.mansfield@
123456lshtm.ac.uk
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.